Axogen (AXGN) said Thursday it has priced an underwritten public offering of about 4.9 million shares at $42.50 each, with gross proceeds expected to be about $208.7 million.
Underwriters have been granted a 30-day option to purchase up to 736,500 additional shares.
The offering is expected to close on Friday.
The company plans to use the net proceeds from the offering to fund the acquisition of BioCircuit Technology, with the remaining proceeds to be used for general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.